| Literature DB >> 31673377 |
Jennifer M Pearson1, Edward Pajor1, John Campbell2, Michel Levy1, Nigel Caulkett3, M Claire Windeyer1.
Abstract
BACKGROUND: The objectives of this study were to investigate the impact of pain mitigation at birth to assisted beef calves and determine the risk factors associated with transfer of passive immunity (TPI), health, and growth.Entities:
Keywords: assisted calving; beef calf; calf health; meloxicam; passive immunity
Year: 2019 PMID: 31673377 PMCID: PMC6803011 DOI: 10.1136/vetreco-2019-000364
Source DB: PubMed Journal: Vet Rec Open ISSN: 2052-6113
Calving management strategies on 15 cow–calf ranches located in southern Alberta during the 2017 calving season
| Management practice | Number of Ranches | |
| Heifers (n=14)* | Cows (n=15) | |
| Frequency of checking dams during daylight hours | ||
| Every 1–2 hours | 7 | 4 |
| 3–6 times a day | 5 | 9 |
| Twice a day | 2 | 2 |
| Frequency of checking dams during night hours | ||
| Every 1–2 hours | 5 | 2 |
| 3–6 times at night | 3 | 4 |
| Twice at night | 5 | 6 |
| Do not check dams at night | 1 | 3 |
| Time to intervene after dam water bag or feet showed (minutes) | ||
| 30–60 | 4 | 4 |
| 60–90 | 6 | 3 |
| 90–120 | 1 | 2 |
| >120 | 3 | 6 |
| Time to intervene after dam is not showing progression with labour (minutes) | ||
| 30–60 | 11 | 9 |
| 60–90 | 2 | 3 |
| 90–120 | 0 | 1 |
| >120 | 1 | 2 |
*One ranch did not calve heifers during the 2017 calving season.
Demographics of 225 beef calves by medication group
| Demographics | Placebo | Meloxicam | Total | |||
| Count | Percentage | Count | Percentage | Count | Percentage | |
| Parity of dam | ||||||
| Heifer | 74 | 66.7 | 77 | 71.3 | 151 | 68.9 |
| Cow | 37 | 33.3 | 31 | 28.7 | 68 | 31.1 |
| Sex of calf | ||||||
| Heifer | 42 | 36.8 | 33 | 30.8 | 75 | 33.9 |
| Bull | 72 | 63.2 | 74 | 69.2 | 146 | 66.1 |
| Twin | ||||||
| No | 108 | 97.3 | 105 | 97.2 | 213 | 97.3 |
| Yes | 3 | 2.7 | 3 | 2.8 | 6 | 2.7 |
| Calving difficulty | ||||||
| Easy assist | 50 | 44.6 | 58 | 54.2 | 108 | 49.3 |
| Difficult assist | 59 | 52.7 | 48 | 44.9 | 107 | 48.9 |
| Caesarean section | 3 | 2.7 | 1 | 0.9 | 4 | 1.8 |
| Presentation of calf | ||||||
| Anterior | 92 | 90.2 | 91 | 88.3 | 183 | 89.3 |
| Posterior | 10 | 9.8 | 12 | 11.7 | 22 | 10.7 |
| Meconium staining | ||||||
| No | 81 | 84.4 | 81 | 84.4 | 96 | 50.0 |
| Yes | 15 | 15.6 | 15 | 15.6 | 96 | 50.0 |
Calves were administered a dose of either subcutaneous meloxicam (Metacam, 20 mg/ml, 0.5 mg/kg bodyweight, Boehringer Ingelheim, Ingelheim, Germany) or placebo (0.025 ml/kg) at birth. All parameters are presented as counts and percentages.
Vigour assessment and colostrum management for 225 beef calves by medication group
| Variable | Placebo | Meloxicam | Total | |||
| Count | Percentage | Count | Percentage | Count | Percentage | |
| Tongue pinch withdrawal | ||||||
| Complete | 76 | 71.0 | 78 | 75.7 | 154 | 73.3 |
| Incomplete | 31 | 29.0 | 25 | 24.3 | 56 | 26.7 |
| Suckle reflex | ||||||
| Strong | 59 | 57.3 | 56 | 55.4 | 115 | 56.4 |
| Weak | 44 | 42.7 | 45 | 44.6 | 89 | 43.6 |
| Mucous membrane colour | ||||||
| Normal | 70 | 65.4 | 64 | 62.1 | 134 | 63.8 |
| Abnormal | 37 | 34.6 | 39 | 37.9 | 76 | 36.2 |
| Time to stand | ||||||
| 0–30 minutes | 20 | 22.7 | 20 | 24.1 | 40 | 23.5 |
| 30–60 minutes | 36 | 40.9 | 27 | 32.6 | 63 | 36.8 |
| 1–6 hours | 28 | 31.8 | 30 | 36.1 | 58 | 33.9 |
| Required assistance | 4 | 4.6 | 6 | 7.2 | 10 | 5.8 |
| Method of colostrum consumption | ||||||
| Nursed from dam | 79 | 78.2 | 73 | 78.5 | 152 | 78.4 |
| Bottle-fed or tube-fed | 22 | 21.8 | 20 | 21.5 | 42 | 21.6 |
| Type of colostrum consumed | ||||||
| Dam’s colostrum | 88 | 83.8 | 82 | 86.3 | 170 | 85.0 |
| Replacer product | 17 | 16.2 | 13 | 13.7 | 30 | 15.0 |
| Calf nursed from the dam | ||||||
| Yes | 80 | 83.3 | 79 | 88.8 | 159 | 86.4 |
| No | 15 | 16.7 | 10 | 11.2 | 25 | 13.6 |
| Time to consume colostrum (hours) | ||||||
| <1 | 20 | 19.8 | 19 | 19.6 | 39 | 19.7 |
| 1–2 | 22 | 21.8 | 21 | 21.6 | 43 | 21.7 |
| 2–3 | 27 | 26.7 | 28 | 28.9 | 55 | 27.8 |
| 3–4 | 19 | 18.8 | 22 | 22.7 | 41 | 20.7 |
| 4+ | 13 | 12.9 | 7 | 7.2 | 20 | 10.1 |
Calves were administered a dose of either subcutaneous meloxicam (Metacam, 20 mg/ml, 0.5 mg/kg bodyweight, Boehringer Ingelheim, Ingelheim, Germany) or placebo (0.025 ml/kg) at birth. All variables are presented as counts and percentages.
Multilevel linear regression models of serum IgG concentrations and average daily gain to weaning in 219 beef calves assisted at birth and medicated with subcutaneous meloxicam (Metacam, 20 mg/ml, 0.5 mg/kg bodyweight, Boehringer Ingelheim, Ingelheim, Germany) or placebo (0.025 ml/kg) while adjusting for covariates and clustering by ranch
| Coefficient | se | P value | Proportion of variance (%) | ||
| Individual level | Ranch level | ||||
| Serum IgG concentration, g/l | >99 | <1 | |||
| Medication group | |||||
| Placebo | Referent | – | |||
| Meloxicam | 3.6 | 2.6 | 0.2 | ||
| Method of colostrum consumption | |||||
| Nursed from cow | Referent | – | |||
| Bottle-fed or tube-fed | −8.5 | 3.2 | 0.008 | ||
| Average daily gain to weaning, kg/day | 96.8 | 3.2 | |||
| Medication group | |||||
| Placebo | Referent | – | |||
| Meloxicam | 0.02 | 0.03 | 0.4 | ||
| Dam parity | |||||
| Mature cow | Referent | – | |||
| Heifer | −0.1 | 0.04 | 0.02 | ||
| Birth weight, kg | 0.009 | 0.002 | <0.0005 | ||
| Serum IgG concentration, g/l | 0.002 | 0.0008 | 0.008 | ||
Multilevel logistic regression models of transfer of passive immunity, treatment for disease, and mortality in calves assisted at birth and medicated with subcutaneous meloxicam (Metacam, 20 mg/ml, 0.5 mg/kg bodyweight, Boehringer Ingelheim, Ingelheim, Germany) or placebo (0.025 ml/kg) while adjusting for covariates and clustering by ranch
| Odds ratio | se | P value | Proportion of variance | ||
| Individual level | Ranch level | ||||
| Inadequate transfer of passive immunity (<24 g/l IgG) | >99 | <1 | |||
| Medication group | |||||
| Placebo | Referent | – | |||
| Meloxicam | 0.6 | 0.2 | 0.2 | ||
| Suckle reflex | |||||
| Strong | Referent | – | |||
| Weak | 0.5 | 0.2 | 0.05 | ||
| Treatment for disease | 46 | 54 | |||
| Medication group | |||||
| Placebo | Referent | – | |||
| Meloxicam | 1.7 | 1.0 | 0.4 | ||
| Tongue withdrawal reflex | |||||
| Complete | Referent | – | |||
| Incomplete | 5.8 | 3.9 | 0.009 | ||
| Mortality | 97.6 | 2.4 | |||
| Medication group | |||||
| Placebo | Referent | – | |||
| Meloxicam | 2.0 | 1.4 | 0.3 | ||
| Meconium staining | |||||
| No | Referent | – | |||
| Yes | 5.4 | 3.8 | 0.02 | ||
| Serum IgG concentration, g/l | 0.95 | 0.02 | 0.03 | ||